MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab Post date September 28, 2025 ← MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update → MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab
